XBP1 and pancreatic neoplasm: Importantly, short-term lenalidomide exposure further increased the proportion of CD45RO+CCR7+ central memory CD3+CD8+ T cell subset within the XBP1-CTL, leading to enhanced anti-tumor activities against breast cancer, colon cancer and pancreatic cancer cells.